Academic Journal
Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy
| Title: | Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy |
|---|---|
| Authors: | Anthony F. Yu, MD, Chaya S. Moskowitz, PhD, Katherine Lee Chuy, MD, Ji Yang, MD, Chau T. Dang, MD, Jennifer E. Liu, MD, Kevin C. Oeffinger, MD, Richard M. Steingart, MD |
| Source: | JACC. CardioOncology, Vol 2, Iss 2, Pp 166-175 (2020) |
| Publisher Information: | Elsevier, 2020. |
| Publication Year: | 2020 |
| Collection: | LCC:Diseases of the circulatory (Cardiovascular) system LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | breast cancer, cardiac monitoring, cardio-oncology, cardiotoxicity, heart failure, Diseases of the circulatory (Cardiovascular) system, RC666-701, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Background: Guidelines recommend left ventricular ejection fraction (LVEF) assessments every 3 months for cardiotoxicity monitoring during human epidermal growth factor receptor 2 (HER2) targeted therapy. Evidence in support of this practice is lacking. Objectives: This study examines the association between adherence to cardiotoxicity surveillance guidelines and heart failure (HF) in HER2-positive breast cancer patients. Methods: A case-control study was performed in 53 patients who developed cardiotoxicity during HER2 targeted therapy, and 159 controls matched by age, anthracycline exposure, and year of treatment. Cardiotoxicity was defined as HF (New York Heart Association functional class III or IV) or cardiac death. Adherence to cardiotoxicity surveillance guidelines was ascertained from the beginning of HER2 targeted therapy to the diagnosis date of HF for cases or the corresponding timepoint for matched controls. Conditional logistic regression was used for case-control comparisons. Results: Eighty-one percent of cases and controls were previously treated with an anthracycline. Adherence to cardiotoxicity surveillance guidelines during the entire observation period or during the first 6 months of treatment was not associated with lower risk of HF. An LVEF |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2666-0873 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2666087320300703; https://doaj.org/toc/2666-0873 |
| DOI: | 10.1016/j.jaccao.2020.03.002 |
| Access URL: | https://doaj.org/article/718f7b62478341409f1af3fdaaba9c1b |
| Accession Number: | edsdoj.718f7b62478341409f1af3fdaaba9c1b |
| Database: | Directory of Open Access Journals |
| ISSN: | 26660873 |
|---|---|
| DOI: | 10.1016/j.jaccao.2020.03.002 |
| Published in: | JACC. CardioOncology |
| Language: | English |